138 related articles for article (PubMed ID: 28521076)
1. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
Matsumoto K; Shichino H; Kawamoto H; Kosaka Y; Chin M; Kato K; Mugishima H
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521076
[TBL] [Abstract][Full Text] [Related]
2. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
Li Z; Tan F; Liewehr DJ; Steinberg SM; Thiele CJ
J Natl Cancer Inst; 2010 Jun; 102(11):758-70. PubMed ID: 20463309
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
9. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
10. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
11. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Li Z; Oh DY; Nakamura K; Thiele CJ
Cancer; 2011 Dec; 117(23):5412-22. PubMed ID: 21590687
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
[TBL] [Abstract][Full Text] [Related]
13. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Cho DC; Hutson TE; Samlowski W; Sportelli P; Somer B; Richards P; Sosman JA; Puzanov I; Michaelson MD; Flaherty KT; Figlin RA; Vogelzang NJ
Cancer; 2012 Dec; 118(24):6055-62. PubMed ID: 22674198
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
15. Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K; Kagabu M; Mizuno M; Oda K; Aoki D; Mabuchi S; Kamiura S; Yamaguchi S; Aoki Y; Saito T; Yunokawa M; Takehara K; Okamoto A; Ochiai K; Kimura T
Invest New Drugs; 2017 Dec; 35(6):800-812. PubMed ID: 28864978
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Mortarini R; Viviani S; Russo D; Marchianò A; Sorasio R; Dodero A; Farina L; Giordano L; Di Nicola M; Anichini A; Corradini P; Gianni AM
Clin Cancer Res; 2014 Nov; 20(22):5641-51. PubMed ID: 25239609
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
[TBL] [Abstract][Full Text] [Related]
19. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Ghobrial IM; Roccaro A; Hong F; Weller E; Rubin N; Leduc R; Rourke M; Chuma S; Sacco A; Jia X; Azab F; Azab AK; Rodig S; Warren D; Harris B; Varticovski L; Sportelli P; Leleu X; Anderson KC; Richardson PG
Clin Cancer Res; 2010 Feb; 16(3):1033-41. PubMed ID: 20103671
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
